High ANKZF1 expression is associated with poor overall survival and recurrence-free survival in colon cancer

2019 ◽  
Vol 15 (18) ◽  
pp. 2093-2106 ◽  
Author(s):  
Xin Zhou ◽  
Yan-Na Shang ◽  
Ran Lu ◽  
Chuan-Wen Fan ◽  
Xian-Ming Mo
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Recurrence Free Survival ◽  
Poor Overall Survival ◽  
Free Survival

Circulating tumor cell (CTC) as a significant prognostic factor in resected primary lung cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e23044-e23044 ◽  
Author(s):  
Kazue Yoneda ◽  
Masaki Hashimoto ◽  
Teruhisa Takuwa ◽  
Seiji Matsumoto ◽  
Yoshitomo Okumura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Survival Rate ◽  
Primary Lung Cancer ◽  
Circulating Tumor Cell ◽  
Small Cell ◽  
Recurrence Free Survival ◽  
Poor Overall Survival ◽  
Free Survival

e23044 Background: Circulating tumor cell (CTC) is a potentially useful marker in early diagnosis and monitoring therapeutic effects for patients with malignant tumors, but clinical significance of CTC in primary lung cancer remains unclear. We previously showed that CTC was a useful surrogate marker of distant metastasis in primary lung cancer (Clin Cancer Res 2009). In this study, we evaluated the prognostic value among completely resected patients after long-term follow-up. Methods: A total of 94 patients (median age, 68 years; 30 females and 64 males) who underwent complete resection for primary lung cancer (4 with small cell and 90 with non-small cell) were prospectively evaluated. At the time of enrollment into the study, 7.5mL of peripheral blood was sampled from each patient, and an EpCAM-based detection system (CellSearch) was used for detection of CTC. CTC was detected in 16 patients (CTC-positive, 14.9%). Results: CTC-positivity was significantly associated with a poor recurrence-free survival (5-year recurrence-free survival rate, 40% versus 72%; p<0.01) (Table 1), which was confirmed by a multivariate analysis (hazard ratio, 2.57 [95% CI, 1.26-5.26]; P=0.010). CTC-positivity was also associated with a poor overall survival (5-year recurrence-free survival rate, 62% versus 84%; p<0.05) (Table 1), which was confirmed by a multivariate analysis (hazard ratio, 2.76 [95% CI, 1.14-6.71]; P=0.025). Conclusions: CTC-positivity was associated with poor recurrence-free survival and poor overall survival in resected lung cancer. [Table: see text]

scholarly journals Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5957
Author(s):  
Marc Riffet ◽  
Yassine Eid ◽  
Maxime Faisant ◽  
Audrey Fohlen ◽  
Benjamin Menahem ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Hippo Pathway ◽  
Promoter Hypermethylation ◽  
Recurrence Free Survival ◽  
Poor Prognostic Factor ◽  
Free Survival ◽  
Colon Cancers ◽  
Genes Encoding

The aims of this study were to assess the frequency of promoter hypermethylation of the genes encoding the Ras associated domain family (RASSF)/Hippo pathway, as well as the impact on overall (OS) and progression-free survival (PFS) in a single-center retrospective cohort of 229 patients operated on for colon cancers. Hypermethylation status was investigated by methylation-specific PCR on the promoters of the RASSF1/2, STK4/3 (encoding Mammalian Ste20-like protein 1 and 2 (MST1 and 2), respectively), and LATS1/2 genes. Clinicopathological characteristics, recurrence-free survival, and overall survival were analysed. We found the RASSF/Hippo pathway to be highly silenced in colon cancer, and particularly RASSF2 (86%). The other promoters were hypermethylated with a lesser frequency of 16, 3, 1, 10 and 6%, respectively for RASSF1, STK4, STK3, LATS1, and LATS2 genes. As the hypermethylation of one RASSF/Hippo family member was by no means exclusive from the others, 27% of colon cancers displayed the hypermethylation of at least two RASSF/Hippo member promotors. The median overall survival of the cohort was 60.2 months, and the median recurrence-free survival was 46.9 months. Survival analyses showed a significantly poorer overall survival of patients when the RASSF2 promoter was hypermethylated (p = 0.03). The median OS was 53.5 months for patients with colon cancer with a hypermethylated RASSF2 promoter versus still not reached after 80 months follow-up for other patients, upon univariate analysis (HR = 1.86, [95% CI: 1.05–3.3], p < 0.03). Such difference was not significant for relapse-free survival as in multivariate analysis. A logistic regression model showed that RASSF2 hypermethylation was an independent factor. In conclusion, RASSF2 hypermethylation is a frequent event and an independent poor prognostic factor in colon cancer. This biomarker could be investigated in clinical practice.

scholarly journals Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma

Tumor Biology ◽  
2017 ◽  
Vol 39 (2) ◽  
pp. 101042831769141 ◽  
Author(s):  
Haijian Zhang ◽  
Yidong Liu ◽  
Huyang Xie ◽  
Qiang Fu ◽  
Zheng Liu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Recurrence Free Survival ◽  
Poor Overall Survival ◽  
Cell Renal Cell Carcinoma ◽  
Fuhrman Grade ◽  
Free Survival

Beta-1,4-galactosyltransferase II is found to be associated with the alterations of tumor-related glycosylation. However, the clinical significance of beta-1,4-galactosyltransferase II in non-metastatic clear-cell renal cell carcinoma has not been reported up to now. Herein, our researches suggested that the expression level of beta-1,4-galactosyltransferase II was first found to be positively associated with tumor size, Fuhrman grade, lymphovascular invasion, rhabdoid differentiation, tumor necrosis and poor overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma, both in training set and validation set. Moreover, beta-1,4-galactosyltransferase II expression was identified as an independent adverse prognosticator for overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma. Ultimately, prognostic accuracy of the nomogram integrating beta-1,4-galactosyltransferase II with other independent prognostic parameters was dramatically improved for overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma. Taken together, beta-1,4-galactosyltransferase II is a potential independent adverse prognostic factor for postoperative recurrence and survival, which could be developed as a useful biomarker for non-metastatic clear-cell renal cell carcinoma by a series of further independent and retrospective studies, so as to help the postsurgical management of clear-cell renal cell carcinoma patients.

scholarly journals AberrantKIF20Aexpression might independently predict poor overall survival and recurrence-free survival of hepatocellular carcinoma

IUBMB Life ◽  
2018 ◽  
Vol 70 (4) ◽  
pp. 328-335 ◽  
Author(s):  
Mingqin Lu ◽  
Xiaoying Huang ◽  
Yongping Chen ◽  
Yangyang Fu ◽  
Chaona Xu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Recurrence Free Survival ◽  
Poor Overall Survival ◽  
Free Survival
Sign in / Sign up

Export Citation Format

Share Document